{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-004527","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.721905+00:00","generated_at":"2026-05-28T05:22:11.130960+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"AlloVir announces 1-for-23 reverse stock split effective Jan 15, 2025","bullets":["Board approved 1-for-23 reverse stock split; effective 4:05 PM ET Jan 15, 2025.","Stock to trade on split-adjusted basis on Nasdaq from Jan 16, 2025; CUSIP 019818202.","No fractional shares; cash payment in lieu at closing price on Jan 15.","Reverse split authorized by stockholders at special meeting on Jan 9, 2025 in connection with proposed merger with Kalaris Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-004527","json":"https://secwatch.observer/filing/0001193125-25-004527.json","markdown":"https://secwatch.observer/filing/0001193125-25-004527.md","text":"https://secwatch.observer/filing/0001193125-25-004527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/0001193125-25-004527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/d834173d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:22:11.130960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}